Teva updated full-year 2026 outlook for expected impact of Emalex Biosciences acquisition
Teva reports Q1 2026 results with revenue $4.0B and non-GAAP EPS $0.53, updates full-year 2026 outlook
- Board has directed management to plan a share repurchase program following Q1 2026 results.
- Updated full-year 2026 outlook now incorporates expected impact of the Emalex Biosciences acquisition.
- Teva to acquire Emalex Biosciences for $700M cash plus up to $200M in milestones and royalties.
- Deal adds NDA-ready Tourette syndrome drug candidate ecopipam to Teva's neuroscience pipeline from Emalex Biosciences.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.